Marc Bitoun

List of Publications by Year
in descending order

55 papers	7,446 citations	159358 30 h-index	155451 55 g-index
60 all docs	60 docs citations	60 times ranked	15437 citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
2	Mutations in dynamin 2 cause dominant centronuclear myopathy. Nature Genetics, 2005, 37, 1207-1209.	9.4	390
3	Dynamin 2 mutations cause sporadic centronuclear myopathy with neonatal onset. Annals of Neurology, 2007, 62, 666-670.	2.8	136
4	Characterization of the muscle involvement in dynamin 2-related centronuclear myopathy. Brain, 2006, 129, 1463-1469.	3.7	121
5	Mutation spectrum in the large GTPase dynamin 2, and genotype-phenotype correlation in autosomal dominant centronuclear myopathy. Human Mutation, 2012, 33, 949-959.	1.1	115
6	Dynamin 2 and human diseases. Journal of Molecular Medicine, 2010, 88, 339-350.	1.7	112
7	A centronuclear myopathy-dynamin 2 mutation impairs skeletal muscle structure and function in mice. Human Molecular Genetics, 2010, 19, 4820-4836.	1.4	107
8	â€œNecklaceâ€•fibers, a new histological marker of late-onset MTM1-related centronuclear myopathy. Acta Neuropathologica, 2009, 117, 283-291.	3.9	106
9	Centronuclear myopathy due to a de novo dominant mutation in the skeletal muscle ryanodine receptor (RYR1) gene. Neuromuscular Disorders, 2007, 17, 338-345.	0.3	105
10	Expanding the clinical, pathological and MRI phenotype of DNM2-related centronuclear myopathy. Neuromuscular Disorders, 2010, 20, 229-237.	0.3	100
11	Recessive RYR1 mutations cause unusual congenital myopathy with prominent nuclear internalization and large areas of myofibrillar disorganization. Neuropathology and Applied Neurobiology, 2011, 37, 271-284.	1.8	97
12	Centronuclear Myopathies. Seminars in Pediatric Neurology, 2011, 18, 250-256.	1.0	84
13	An alternative mechanism of clathrin-coated pit closure revealed by ion conductance microscopy. Journal of Cell Biology, 2012, 197, 499-508.	2.3	77
14	Dynamin 2 mutations associated with human diseases impair clathrin-mediated receptor endocytosis. Human Mutation, 2009, 30, 1419-1427.	1.1	76
15	Adult-onset autosomal dominant centronuclear myopathy due to BIN1 mutations. Brain, 2014, 137, 3160-3170.	3.7	76
16	PHENOTYPE OF A PATIENT WITH RECESSIVE CENTRONUCLEAR MYOPATHY AND A NOVEL BIN1 MUTATION. Neurology, 2010, 74, 519-521.	1.5	73
17	Actin scaffolding by clathrin heavy chain is required for skeletal muscle sarcomere organization. Journal of Cell Biology, 2014, 205, 377-393.	2.3	60
18	Gene expression of the transporters and biosynthetic enzymes of the osmolytes in astrocyte primary cultures exposed to hyperosmotic conditions. Glia, 2000, 32, 165-176.	2.5	52

#	Article	IF	Citations
19	A Centronuclear Myopathy â€“ Dynamin 2 Mutation Impairs Autophagy in Mice. Traffic, 2012, 13, 869-879.	1.3	52
20	Reducing dynamin 2 (DNM2) rescues DNM2 -related dominant centronuclear myopathy. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 11066-11071.	3.3	50
21	Gene expression of taurine transporter and taurine biosynthetic enzymes in brain of rats with acute or chronic hyperosmotic plasma. Molecular Brain Research, 2000, 77, 10-18.	2.5	48
22	A novel mutation in the dynamin 2 gene in a Charcot-Marie-Tooth type 2 patient: Clinical and pathological findings. Neuromuscular Disorders, 2008, 18, 334-338.	0.3	43
23	Phenotype variability and histopathological findings in centronuclear myopathy due to DNM2 mutations. Journal of Neurology, 2011, 258, 1085-1090.	1.8	43
24	A NEW CENTRONUCLEAR MYOPATHY PHENOTYPE DUE TO A NOVEL DYNAMIN 2 MUTATION. Neurology, 2009, 72, 93-95.	1.5	42
25	Vici syndrome associated with sensorineural hearing loss and evidence of neuromuscular involvement on muscle biopsy. American Journal of Medical Genetics, Part A, 2010, 152A, 741-747.	0.7	40
26	Alleleâ€specific silencing therapy for Dynamin 2â€related dominant centronuclear myopathy. EMBO Molecular Medicine, 2018, 10, 239-253.	3.3	40
27	Clathrin plaques and associated actin anchor intermediate filaments in skeletal muscle. Molecular Biology of the Cell, 2019, 30, 579-590.	0.9	40
28	Dynamin-2 mutations linked to Centronuclear Myopathy impair actin-dependent trafficking in muscle cells. Scientific Reports, 2017, 7, 4580.	1.6	37
29	Skeletal Muscle Biopsy Analysis in Reducing Body Myopathy and Other FHL1-Related Disorders. Journal of Neuropathology and Experimental Neurology, 2013, 72, 833-845.	0.9	36
30	Taurine Down-Regulates Basal and Osmolarity-Induced Gene Expression of Its Transporter, but Not the Gene Expression of Its Biosynthetic Enzymes, in Astrocyte Primary Cultures. Journal of Neurochemistry, 2002, 75, 919-924.	2.1	32
31	Gene expression of the taurine transporter and taurine biosynthetic enzymes in rat kidney after antidiuresis and salt loading. Pflugers Archiv European Journal of Physiology, 2001, 442, 87-95.	1.3	31
32	Alternative splicing of clathrin heavy chain contributes to the switch from coated pits to plaques. Journal of Cell Biology, 2020, 219, .	2.3	31
33	A DNM2 Centronuclear Myopathy Mutation Reveals a Link between Recycling Endosome Scission and Autophagy. Developmental Cell, 2020, 53, 154-168.e6.	3.1	30
34	Gene Therapy via Trans-Splicing for LMNA-Related Congenital Muscular Dystrophy. Molecular Therapy - Nucleic Acids, 2018, 10, 376-386.	2.3	29
35	Regional Expression and Histological Localization of Cysteine Sulfinate Decarboxylase mRNA in the Rat Kidney¹. Journal of Histochemistry and Cytochemistry, 2000, 48, 1461-1468.	1.3	22
36	Impaired excitationâ€“contraction coupling in muscle fibres from the dynamin2^{R465W} mouse model of centronuclear myopathy. Journal of Physiology, 2017, 595, 7369-7382.	1.3	22

#	Article	IF	Citations
37	Correlative SICMâ€FCM reveals changes in morphology and kinetics of endocytic pits induced by diseaseâ€associated mutations in dynamin. FASEB Journal, 2019, 33, 8504-8518.	0.2	21
38	Characterization of the cDNA Coding for Rat Brain Cysteine Sulfinate Decarboxylase. Journal of Neurochemistry, 2001, 73, 903-912.	2.1	20
39	A review of Dynamin 2 involvement in cancers highlights a promising therapeutic target. Journal of Experimental and Clinical Cancer Research, 2021, 40, 238.	3.5	19
40	Therapy for Dominant Inherited Diseases by Allele-Specific RNA Interference: Successes and Pitfalls. Current Gene Therapy, 2015, 15, 503-510.	0.9	19
41	Nuclear defects in skeletal muscle from a Dynamin 2-linked centronuclear myopathy mouse model. Scientific Reports, 2019, 9, 1580.	1.6	17
42	Neuromuscular expression of the BTB/POZ and zinc finger protein myoneurin. Muscle and Nerve, 2004, 29, 59-65.	1.0	15
43	Calcium homeostasis alterations in a mouse model of the Dynamin 2-related centronuclear myopathy. Biology Open, 2016, 5, 1691-1696.	0.6	15
44	Reprogramming the Dynamin 2 mRNA by Spliceosome-mediated RNA Trans-splicing. Molecular Therapy - Nucleic Acids, 2016, 5, e362.	2.3	10
45	BIN1 modulation inÂvivo rescues dynamin-related myopathy. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	10
46	Role of dynamin 2 in the disassembly of focal adhesions. Journal of Molecular Medicine, 2013, 91, 803-809.	1.7	7
47	Loss of Dynamin 2 <scp>GTP</scp>ase function results in microcytic anaemia. British Journal of Haematology, 2017, 178, 616-628.	1.2	7
48	Satellite cells deficiency and defective regeneration in dynamin 2â€related centronuclear myopathy. FASEB Journal, 2021, 35, e21346.	0.2	7
49	Cysteine Sulfinate Decarboxylase (CSD): Molecular Cloning, Sequence and Genomic Expression in Brain. Advances in Experimental Medicine and Biology, 1998, 442, 25-32.	0.8	5
50	C.P.4.11 Ragged red fibres finding in muscle biopsy of dynamin 2-related centronuclear myopathy. Neuromuscular Disorders, 2007, 17, 881-882.	0.3	4
51	Muscle regeneration affects Adeno Associated Virus 1 mediated transgene transcription. Scientific Reports, 2022, 12, .	1.6	4
52	G.P.8 11 Towards the identification of new morphological subtypes of congenital myopathy. Neuromuscular Disorders, 2006, 16, 709-710.	0.3	1
53	Expression of the transcriptional repressor gene myoneurin at the neuromuscular junction, during mouse development and in the adult. Journal of Physiology (Paris), 2006, 99, 1.	2.1	1
54	Benefits of therapy by dynamin-2-mutant-specific silencing are maintained with time in a mouse model of dominant centronuclear myopathy. Molecular Therapy - Nucleic Acids, 2022, 27, 1179-1190.	2.3	1

#	Article	IF	Citations
55	G.O. 10 Dynamin 2 mutations and impairment of EGF-induced MAPK activation. Neuromuscular Disorders, 2006, 16, 725-726.	0.3	0